Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: CHF 4226 pMDI
Drug: Placebo

Registration Number: NCT00782535

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Brief Summary: The purpose of this study is to characterize the dose-response profile of peak and trough FEV1 after single dose administrations of carmoterol in patients with COPD.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 20

Inclusion Criteria

Patient has signed an IRB approved Informed Consent form and the written informed consent was obtained prior to any study-related procedure(s)
Patient is a male or non-pregnant female, 40 -75 years old, inclusive
Patient has a current or past cigarette smoking history of at least 15 pack-years
Patient has a clinical diagnosis of COPD in accordance with the recommendations of the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO) Global Initiative for Chronic Obstructive Lung Disease (GOLD)
Patient meets the following requirements after an FEV1 albuterol reversibility test (i.e., 30 minutes following 400µg (metered dose) albuterol MDI):
FEV1/FVC < 70%
FEV1 is at least 0.9L
FEV1 30% - 80%, inclusive, of patient's predicted normal value
∆FEV1 > 5% of pre-albuterol value
If ∆FEV1 </= 5% of pre-albuterol value, then this requirement must be met after retesting during the run-in period, at least 24 hours prior to Visit 2.

Exclusion Criteria

Patient has a history of asthma
Patient has a blood eosinophil count > 500/µL
Patient has a history of allergic rhinitis or atopy
Patient had a COPD exacerbation or a lower respiratory tract infection within 8 weeks prior to screening, or during the run-in period, that resulted in the use of an antibiotic, or oral or parenteral corticosteroids
Patient is on an inhaled corticosteroid that has been initiated, or the effective dose has been changed, within 4 weeks prior to screening or during the run-in period
Patient has an uncontrolled cardiovascular (e.g., uncontrolled hypertension), respiratory, hematologic, immunologic, renal, neurologic, hepatic, endocrine (e.g., uncontrolled diabetes mellitus) or other disease, or any condition that might, in the judgment of the Investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study
Patient has clinically significant abnormal routine hematology (e.g., anemia) and/or clinical chemistry value(s).
Patient has a history of coronary artery disease, cerebrovascular disease, cardiac arrhythmias
Patient has lung cancer or a history of lung cancer
Patient has active cancer or a history of cancer with less than 5 years disease free survival time (whether or not there is evidence of local recurrence or metastases). Localized basal cell carcinoma (without metastases) of the skin is acceptable.
Patient has a serum potassium value ≤ 3.5 mEq/L or > 5.5mEq/L and/or a fasting serum glucose value ≥ 140 mg/dL
Patient has an abnormal QTcF interval value in the Screening visit ECG test (i.e., > 450 msec in males or > 470 msec in females)
Patient has developed Cor Pulmonale
Patient is receiving long term oxygen therapy, i.e., > 16 hours/24-hour period, every day, unless residing at an elevation > 4000ft
Patient has used any of the following medications prior to Screening and has not met the specified minimum washout period:
Long acting anti-cholinergic agent (i.e., tiotropium): 7 days
Short acting anti-cholinergics: 8 hours
Fixed combinations of β2-agonists and inhaled corticosteroids: 48 hours
Fixed combinations of an anti-cholinergic and short acting β2-agonist: 8 hours
Long-acting β2-agonists: 48 hours
Short acting β2-agonists: 6 hours
Theophylline and other xanthines: 1 week
Parenteral or oral corticosteroids: 1 month
Patient has taken any non-permitted medication
Patient has received a live-attenuated virus vaccination within two weeks prior to screening or during the run-in (inactivated Influenza vaccination is acceptable provided it is not administered within 48 hours prior to Screening)
Patient has a known intolerance/hypersensitivity to β2-adrenergic agonists, propellant gases/excipients
Patient is pregnant or lactating female, or female physiologically capable of becoming pregnant UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL OR are using one or more of the following acceptable methods of contraception:
surgical sterilization (e.g., bilateral tubal ligation, hysterectomy)
hormonal contraception (implantable, patch, oral)
double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap)
Patient is male and does not agree to use a medically acceptable contraceptive (abstain from sexual intercourse, or use a condom with spermicide), or has not had a vasectomy at least 6 months prior to study participation, unless their sexual partner is not of child-bearing potential
Patient is mentally or legally incapacitated
Patient has participated in another investigational study within 30 days prior to screening
Patient abuses alcohol or other substances
Patient does not maintain regular day/night, waking/sleeping cycles (e.g., night shift worker)
Patient is potentially non-compliant or unable to perform required outcome measurements of the protocol

Study & Design

Study Type: INTERVENTIONAL

Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Treatment B	CHF 4226 pMDI	Single therapeutic dose of CHF 4226 pMDI
Treatment A	CHF 4226 pMDI	Single therapeutic dose of CHF 4226 pMDI
Treatment C	CHF 4226 pMDI	Single supratherapeutic dose of CHF 4226 pMDI
Treatment D	CHF 4226 pMDI	Single supratherapeutic dose of CHF 4226 pMDI
Treatment E	Placebo	Single dose of placebo

Primary Outcome Measures

Name	Time	Method
FEV1	T-1hr, T-10min, and 15 and 30 minutes, 1, 2, 3, 23 and 24 hours for each treatment period

Secondary Outcome Measures

Name	Time	Method
FVC	T-1hr, T-10min, and 15 and 30 minutes, 1, 2, 3, 23 and 24 hours for each treatment period
serum glucose	pre dose and 1, 4, 6 and 24 hrs post dose for each treatment period
serum potassium	pre dose and 1, 4, 6 and 24 hrs post dose for each treatment period
plasma concentrations of CHF 4226	pre dose and 15 minutes and 2 hours post dose for each treatment period
urinary excretion of CHF 4226	pre dose and 0-24 hrs post dose for each treatment period

Trial Locations

Locations (5): Clinical Research Institute of Southern Oregon, PC
🇺🇸
Medford, Oregon, United States
University Clinical Research DeLand, LLC
🇺🇸
DeLand, Florida, United States
New Horizons Clinical Research Center
🇺🇸
Cincinnati, Ohio, United States
Spartanburg Medical Research
🇺🇸
Spartanburg, South Carolina, United States
Commonwealth Biomedical Research, LLC
🇺🇸
Madisonville, Kentucky, United States